|
|
NME7 |
NME/NM23 family member 7 |
- Recruitment of mitotic centrosome proteins and complexes
- Recruitment of NuMA to mitotic centrosomes
|
|
|
|
|
NSD3 |
nuclear receptor binding SET domain protein 3 |
- PKMTs methylate histone lysines
|
|
|
|
|
OIP5 |
Opa interacting protein 5 |
- Deposition of new CENPA-containing nucleosomes at the centromere
|
|
|
|
|
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- Costimulation by the CD28 family
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- Extra-nuclear estrogen signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
|
- ATP
- Caffeine
- XL765
- Wortmannin
- Pilaralisib
- Alpelisib
- Copanlisib
|
|
|
|
PLEKHB1 |
pleckstrin homology domain containing B1 |
|
|
|
|
|
PLEKHB2 |
pleckstrin homology domain containing B2 |
|
|
|
|
|
POU6F2 |
POU class 6 homeobox 2 |
|
|
|
|
|
PRKAR1B |
protein kinase cAMP-dependent type I regulatory subunit beta |
- PKA activation
- PKA activation in glucagon signalling
- DARPP-32 events
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Vasopressin regulates renal water homeostasis via Aquaporins
- CREB1 phosphorylation through the activation of Adenylate Cyclase
- Hedgehog 'off' state
- ADORA2B mediated anti-inflammatory cytokines production
- FCGR3A-mediated IL10 synthesis
- Factors involved in megakaryocyte development and platelet production
|
|
|
|
|
PRR20A |
proline rich 20A |
|
|
|
|
|
PRR20B |
proline rich 20B |
|
|
|
|
|
PRR20C |
proline rich 20C |
|
|
|
|
|
PRR20D |
proline rich 20D |
|
|
|
|
|
PRR20E |
proline rich 20E |
|
|
|
|
|
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
- Stimuli-sensing channels
- Rap1 signalling
- GP1b-IX-V activation signalling
- CD209 (DC-SIGN) signaling
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by MRAS-complex mutants
|
- Sorafenib
- LErafAON
- XL281
- iCo-007
- Cholecystokinin
- Regorafenib
- Dabrafenib
- Fostamatinib
|
|
|
|
RASSF1 |
Ras association domain family member 1 |
|
|
- Non-small cell lung cancer
- Bladder cancer
- Nasopharyngeal cancer
|
|
|
RBFOX2 |
RNA binding fox-1 homolog 2 |
- FGFR2 alternative splicing
|
|
|
|
|
RBM11 |
RNA binding motif protein 11 |
|
|
|
|
|
RBPMS |
RNA binding protein, mRNA processing factor |
|
|
|
|
|
SHOX |
short stature homeobox |
|
|
- SHOX-related haploinsufficiency disorders, including: Isolated short stature; Langer syndrome; Leri-Weill syndrome
|
|
|
SOX3 |
SRY-box transcription factor 3 |
- Deactivation of the beta-catenin transactivating complex
|
|
- Septo-optic dysplasia
- Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
- 46,XX disorders of sex development (Disorders of gonadal development), including: Ovotesticular DSD; Testicular DSD; Ovarian dysgenesis
- Syndromic X-linked mental retardation, including: Turner type (MRXST); Siderius type (MRXSSD) ; Cabezas type (MRXC); Raymond type (MRXSR); Type10 (MRXS10); Type14 (MRXS14); Mental retardation with isolated growth hormone deficiency (MRGH)
|